TMCnet News
BUYINS.NET: REGN, ASEI, AIRM, IMGN, EIG, POL Expected To Be Higher After Earnings Releases on ThursdayAug 03, 2009 (M2 PRESSWIRE via COMTEX) -- BUYINS.NET / www.squeezetrigger.com is monitoring the performance of all stocks with earnings being released Thursday, August 6th and determining how the stocks have performed after their last 12 quarterly, 6 quarterly and August earnings reports. Regeneron Pharmaceuticals (NASDAQ: REGN), American Science and Engineering (NASDAQ: ASEI), Air Methods Corp (NASDAQ: AIRM), ImmunoGen (NASDAQ: IMGN), Employers Holdings (NYSE: EIG) and PolyOne Corp (NYSE: POL) are all expected to be higher after their earnings are released Thursday. The movement of stock prices in the days and weeks leading to and following these earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The # of Reports in the table below shows how many previous quarterly reports comprise the indicator that predicts how a stock will act after its earnings are released. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php. The following stocks are expected to go higher after earnings are released Thursday: Symbol Company # of Reports Quarter Release Time REGN Regeneron Pharma August earnings Q2 Before ASEI American Science 12 quarters Q1 After AIRM Air Methods Corporation 12 quarters Q2 After IMGN ImmunoGen, Inc. August earnings Q4 After EIG Employers Holdings 12 quarters Q2 After POL PolyOne Corporation August earnings Q2 Before Earnings, or profits, drive stock prices. The market values a company based on its current and anticipated future ability to make money. The market takes the earnings pulse of a company four times per year when quarterly reports are issued. When this information is released it can often be a trend-changing or a trend confirming event because the information is so vital to the market's perception of the vitality of that company. This technology is designed to help the stock trader identify those companies that seem to have a consistent pattern of movement before or after the earnings release date, based on the history of earnings releases for that company. It combines a calendar of expected earnings releases with a history of past earnings releases in a way that lets you see if a pattern exists. Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), an integrated biopharmaceutical company, discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions in the United States. The companyas commercial product includes ARCALYST (rilonacept) injection for subcutaneous use for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children. Its products under Phase III clinical trials include Aflibercept for the treatment of oncology; VEGF Trap-Eye in wet AMD in patients for eye diseases; and ARCALYST versus placebo for the prevention of gout flares in patients initiating urate-lowering drug therapy. The companyas products under clinical trials include REGN88, an antibody to the Interleukin-6 receptor (IL-6R) that is being evaluated in patients with rheumatoid arthritis; REGN421, an antibody to delta-like ligand-4 that is being developed for oncology; and REGN475, an antibody to nerve growth factor, which is being developed for the treatment of pain. Regeneron Pharmaceuticals also conducts other preclinical research programs in the areas of oncology and angiogenesis, ophthalmology, metabolic and related diseases, muscle diseases and disorders, inflammation and immune diseases, bone and cartilage, pain, and cardiovascular diseases. The company has strategic collaboration agreements with sanofi-aventis Group to discover, develop, and commercialize fully human monoclonal antibodies; and Bayer HealthCare LLC for the development of the VEGF-Trap-Eye. Regeneron Pharmaceuticals was founded in 1988 and is based in Tarrytown, New York. American Science and Engineering, Inc. (NASDAQ: ASEI), together with its subsidiary, AS&E Global, Inc., engages in the development, manufacture, marketing, and sale of X-ray inspection and other detection solutions primarily for homeland security markets in the United States and internationally. The company offers CargoSearch Inspection Systems, such as non-intrusive inspection products, which are primarily used for the screening of trucks, cars, cargo containers, pallets, and air cargo at border crossings, seaports, military bases, railroad centers, airports, and cargo and transportation hubs. Its CargoSearch systems include OmniView gantry system, a cargo and vehicle inspection system; Z Portal, an inspection system to scan cars, vans, trucks, and their cargoes for threats and contraband; and Z Gantry, a Z Backscatter inspection system. The company also provides Z Backscatter imaging systems, including Z Backscatter Van, a mobile X-ray screening system to produce photo-like images of plastic explosives or other anomalies of the contents of a vehicle or cargo container. In addition, it offers parcelsearch and personnel screening inspection systems, such as Gemini for the non-intrusive X-ray scanning of parcels, baggage, and mail; and SmartCheck, a personnel screening system for screening contraband and threats hidden under a personas clothing, such as guns and knives, plastic explosives, liquid explosives, composite weapons, and drugs. Further, the company provides contract research and development programs for agencies of the United States government; and maintenance, warranty, research, engineering, and training services. Its customers include authorities responsible for port and border security; military organizations; high threat commercial and government facilities; aviation security agencies; and legal enforcement agencies. American Science and Engineering, Inc. was founded in 1958 and is headquartered in Billerica, Massachusetts. Air Methods Corporation (NASDAQ: AIRM), together with its subsidiaries, provides air medical emergency transport services and systems in the United States. The company operates through three segments: Community-Based Model, Hospital-Based Model, and Products. The Community-Based Model segment provides air medical transportation services, which include medical care, aircraft operation and maintenance, communications and dispatch, and medical billing and collection services. As of December 31, 2008, this segment operated 131 helicopters and 4 fixed wing aircraft. The Hospital-Based Model segment offers air medical transportation services and medically-equipped helicopters and airplanes for hospitals. As of December 31, 2008, this segment operated 191 helicopters and 12 fixed wing aircraft. The Products segment involves in the design, manufacture, and installation of aircraft medical interiors and other aerospace and medical transport products for domestic and international customers. Air Methods Corporation was founded in 1982 and is headquartered in Englewood, Colorado. ImmunoGen, Inc. (NASDAQ: IMGN) engages in the research and development of antibody-based anticancer therapeutics in the United States. The company develops therapeutics for the treatment of cancer using its Tumor-Activated Prodrug (TAP) technology, which uses antibodies to deliver a potent cytotoxic agent. Its products include IMGN242, a Phase I clinical trial product for the treatment of CanAg-expressing gastric, pancreatic, and colorectal cancer; and IMGN901, which is in three clinical trials for the treatment of multiple myeloma as well as other hematological malignancies, small-cell lung cancer, ovarian cancer, and other cancers of neuroendocrine origin. The companyas products also include Trastuzumab-DM1, a Phase II clinical trial product for the treatment of metastatic breast cancer; AVE9633, a Phase I clinical trial product for acute myeloid leukemia; AVE1642, a Phase I clinical trial product for the treatment of certain solid tumors and hematological malignancies; SAR3419, a Phase I clinical trial product for the treatment of B-cell hematological malignancies, including non-Hodgkinas lymphoma; and BIIB015, a Phase I clinical trial product for the treatment of the treatment of solid tumors. It has collaborative partnerships with sanofi-aventis; Genentech, Inc.; Biogen Idec, Inc.; Biotest AG; Centocor, Inc.; Amgen, Inc.; Vernalis; and Cytovance Biologics LLC. ImmunoGen was founded in 1981 and is based in Waltham, Massachusetts. Employers Holdings, Inc. (NYSE: EIG), through its subsidiaries, operates in the commercial property and casualty insurance industry in the United States. The company provides workersa compensation insurance to small businesses engaged in low to medium hazard industries. It distributes its products through independent agents and brokers, as well as through strategic partnerships and alliances. The company is headquartered in Reno, Nevada. PolyOne Corporation (NYSE: POL) provides specialized polymer materials with operations in thermoplastic compounds, specialty polymer formulations, color and additive systems, thermoplastic resin distribution, and specialty polyvinyl chloride (PVC) resins. It also has equity investments in a manufacturer of caustic soda and chlorine, and a formulator of polyurethane compounds. The companyas International Color and Engineered Materials segment offers color and additive masterbatches, and engineered materials. Its Specialty Engineered Materials segment provides custom plastic compounding services and solutions for processors of thermoplastic materials to various markets, as well as offers a range of thermoplastic elastomer compounds for consumer, packaging, and medical applications. PolyOneas Specialty Color, Additives, and Inks segment provides specialized color and additive concentrates, as well as inks and latexes. Its Performance Products and Solutions segment offers vinyl compounds, vinyl resins, and specialty coating materials based on vinyl to various manufacturers of plastic parts and consumer-oriented products, as well as offers materials testing and component analysis, custom compound development, colorant and additive, design assistance, structural analyses, process simulations, and extruder screw design services. The companyas PolyOne Distribution segment distributes engineering and commodity grade resins to custom injection molders and extruders. PolyOneas Resin and Intermediates segment produces chlorine and caustic soda. The company primarily serves building and construction materials, wire and cable, transportation, durable goods, packaging, electrical and electronics, medical, and telecommunications markets. PolyOne sells its products worldwide through direct sales personnel, sales agents, and distributors. The company was founded in 1927 and is headquartered in Avon Lake, Ohio. SqueezeTrigger.com has built a massive database that collects, analyzes and publishes multiple proprietary trading strategies that predict price moves in stocks, commodities and currencies. The data has then been integrated into an automated trading platform which can be used to connect to a live online broker and automate your trading of each of the strategies highlighted. It is extremely powerful with lightening fast execution at a very low price. Both the trading software and SqueezeTrigger data feed are available at http://www.squeezetrigger.com One example from the SqueezeTrigger database is approximately 2.6 billion short sale transactions going back to January 1, 2005, and SqueezeTrigger calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like SqueezeTrigger.com to access the data. Total Short Interest is the number of shares shorted but not yet covered, and is different from total short volume. To access SqueezeTrigger Prices ahead of potential short squeezes beginning, visit http://www.squeezetrigger.com Go to www.SqueezeTrigger.com to find out the exact price that the entire Total Short Interest will start covering! About SQUEEZETRIGGER.COM WWW.SQUEEZETRIGGER.COM is a service designed to help bonafide shareholders of publicly traded US companies fight short selling. SqueezeTrigger.com has built a proprietary database that uses Threshold list feeds and short sale time and sale data from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short trades. SQUEEZETRIGGER.COM has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted. The SqueezeTrigger database of nearly 2.5 billion short sale transactions goes back to January 1, 2005 and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005 because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like SqueezeTrigger.com to access the data. The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each monthas short transactions, SQUEEZETRIGGER.COM provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money and a short squeeze can begin. All material herein was prepared by SQUEEZETRIGGER.COM, based upon information believed to be reliable. The information contained herein is not guaranteed by SQUEEZETRIGGER.COM to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. Occassionally companies pay $995.00 to purchase data for information provided in reports issued by BUYINS.NET, a company affiliated with SQUEEZETRIGGER.COM. The data service can be cancelled at any time. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SQUEEZETRIGGER.COM is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on or mentioned herein. SQUEEZETRIGGER.COM will not advise as to when it decides to sell and does not and will not offer any opinion as to when others should sell; each investor must make that decision based on his or her judgment of the market. SQUEEZETRIGGER.COM and SQUEEZETRIGGER are intended for use by stock market professionals. As a member, visitor, or user of any kind, you accept full responsibilities for your investment and trading actions. The contents of SQUEEZETRIGGER.COM, including but not limited to all implied or expressed views, opinions, teachings, data, graphs, opinions, or otherwise are not predictions, warranty, or endorsements of any kind. Please seek stock market advice from the proper securities professional, or investment advisor. By visiting SQUEEZETRIGGER.COM or using any data or services, you agree to assume full responsibility for the decisions or actions that you undertake. Global Automated Trading Systems, LLC, its owner(s), operators, employees, partners, affiliates, advertisers, information providers and any other associated person or entity, shall under no circumstances be held liable to the user and/or any third party for loss or damages of any kind, including but not limited to trading losses, lost trading opportunity, direct, indirect, consequential, special, incidental, or punitive damages. As a user, you agree that any damages collected shall not exceed the amount paid to SQUEEZETRIGGER.COM and/or its owners. As a website user, you agree that any and all legal matters of any kind are to be reviewed and handled in their entirety within the State of California only. By using the services of this website, you are consenting to the terms as outlined, and forfeit all legal jurisdictions in any other State. Past performance is not a guarantee of future outcomes. Any and all examples are hypothetical and should not be considered a guarantee or endorsement of such trading activity. SQUEEZETRIGGER.COM does not take responsibility for problems of any kind, including but not limited to issues with operations, data accuracy or completeness, contacting issues, technical issues, and timeliness. SQUEEZETRIGGER.COM places great integrity on the data collected and distributed. This information is deemed reliable, but not guaranteed. All information and data is provided "as is" without warranty or guarantee of any kind. Please seek investment and/or trading advice, council, information or services from a securities professional. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SQUEEZETRIGGER.COM undertakes no obligation to update such statements. This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected", "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the SEC. SqueezeTrigger is a registered trademark, Reg. No. 3,120,641 CONTACT: Thomas Ronk, CEO, SqueezeTrigger.com Tel: +1 800 715 9999 e-mail: [email protected] WWW: http://www.SqueezeTrigger.com ((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to [email protected]. |